12 research outputs found
Textbook Brouhaha
No full textAt a time of new controversy over reading material used in Mississippi public schools, Charles W. Eagles’ 2017 book dealing with an epic battle over a state history textbook in the 1970s is the subject of this Overby Center for Southern Journalism and Politics program. Eagles, who retired after more than three decades as a history professor at Ole Miss, talks about “Civil Rights Culture Wars” with K.B. Melear, a professor in the school’s education department. The book deals with a struggle with the politically-controlled state textbook commission to win approval for a new history textbook that covered the civil rights movement, poverty, and issues confronting women, workers and native Americans in Mississippi. The issues had been ignored by textbooks in use in the state
Book Review - American Higher Education: A History
No full textAmerican Higher Education: A History, by Christopher J. Lucas is a historical narrative of the origins and development of the system of higher learning in place in contemporary America. It extends and updates earlier works in this area, and provides, as the author had hoped, "a more 'accessible' historical account, useful chiefly for nonspecialists and a more general readership . . ." but is nonetheless a thorough review of the historical underpinnings of American higher education. This work is recommended for students and professionals who seek a broad understanding of contemporary higher education and how it came to pass
Military Unit Files: Co A 8 Ala. Cav. | Co B 8 Ala. Cav. | Co H 8 Ala. Cav. | Co K 8 Ala. Cav.
No full textThe Confederate Graves Survey Archive of the Texas Division, Sons of Confederate Veterans consists of surveys of cemeteries throughout Texas, and portions of Oklahoma and New Mexico. The surveys document the interment of Confederate States of America military veterans. United States of America (Union) veterans, as well as able-bodied men at the time of the Civil War, are also documented. 13 boxes entitled "Grave Surveys" contain grave surveys listed county-by-county, 3 boxes of "Unit Files" list surveyed individuals by their military unit. Finally, 17 boxes contain "Veteran Files" that document each veteran by name in "last name, first name, middle initial" format. An index that cross-references each of the collection series (Grave Surveys, Unit Files, and Veteran Files) is included, as are institutions to surveyors on how and what to document while conducting surveys.Willow Cemetery #444, Haskell, Haskell County, Texas | Veterans Interred: Quinn, James Knox
.Hansford County Cemetery #163, Hansford County, Texas | Veterans Interred: Gibner, Henry Clay.Val Verde Cemetery #055, Val Verde, Milam County, Texas | Veterans Interred: Melear, J.J.Willow Cemetery #444, Haskell, Haskell County, Texas | Veterans Interred: Robertson, Samuel Luther
Recommended from our members
A Phase 1a/b Trial of Luxeptinib (CG-806) in Patients with Relapsed/Refractory B-Cell Malignancies or Acute Myeloid Leukemia and Evaluation of New G3 Formulation
No full textINTRODUCTION: Luxeptinib (CG-806; LUX) is an orally active noncovalent kinase inhibitor of Bruton's tyrosine kinase (BTK), wild type and mutant forms of Fms-like tyrosine kinase 3 (FLT3) (including the internal tandem duplicates (ITD), tyrosine kinase domain (TKD), and F691L mutant forms), and growth receptors like KIT, CSF1R, PDGFRα, and TRKs. In prior studies, LUX has been shown to suppress aberrant proliferative signaling in B cell malignancies and acute myeloid leukemia (AML) via regulation of BTK, LYN, SYK, AKT, ERK, and MAPK. LUX is cytotoxic to primary AML cells insensitive to other FLT3 inhibitors and to malignant B-cells insensitive to ibrutinib, at pM and nM concentrations, respectively. AIMS: The primary objectives of these studies are to assess the safety, tolerability, and pharmacokinetics (PK) of LUX and determine recommended phase 2 doses for relapsed or refractory (R/R) AML and B cell malignancy patients. METHODS: In two studies (NCT04477291; NCT03893682), LUX (original formulation, G1) was administered continuously as oral capsules BID in 28-day cycles of ascending cohorts (relapsed or refractory de novo, secondary, or therapy-related AML or higher risk myelodysplastic syndrome (MDS), and relapsed and refractory for B cell lymphoma and chronic lymphocytic/small lymphocytic leukemia). A novel generation 3 (G3) formulation of LUX designed to increase bioavailability was tested at a single-dose (sub-study) for relative bioavailability (RBA), followed by continuous dosing in subsequent R/R AML patients. RESULTS: In the B-cell study (as of 15 th May 2023), LUX has been administered to 36 patients at dose levels from 150 mg to 900 mg BID in patients with a median of 3 lines of prior treatment, with 47.2% having received a BTK-inhibitor. Only one (2.8%) patient had a DLT of hypertension and 14 (38.9%) experienced at least one drug related ≥Grade3 treatment emergent adverse event (TEAE). Two patients (900 mg) are currently on study with no DLT and no ≥Grade 3 related TEAEs. A Follicular lymphoma patient is at cycle 28, and achieved a best response as partial response (PR) with a decrease in lesion size of 76.2%; an SLL patient is at cycle 13, and achieved stable disease (SD) showing a decrease in lesion size of 43.1% (Figure A). The overall best response achieved among the 17 patients who have been on treatment for more than 12 weeks are stable disease (SD) (n=11), partial response (PR) (n=3), minor response (n=2) and complete response (CR) (n=1). As of 5 th June 2023, in the AML trial, a total of 40 patients (16 (40%) FLT3-ITD, 21 (52.5%) FLT3-WT, 2 (5.0%) FLT3-TKD, and 1 (2.5%) unknown mutations) with a median of 3 prior treatments (range, 1 - 10) have been treated with LUX G1 formulation at dose levels from 450 mg - 900 mg BID (n=34) or with 50 mg BID of G3 formulation (n=6). Four (10%) experienced drug related SAE and 7 (17.5%) had a drug related grade ≥3 TEAEs. The most common related TEAEs were lymphocyte count decrease, platelet count decrease, and anemia (n=2; 5% patients each). One (2.5%) patient at 450 mg dose, reported complete remission without minimum residual disease (CRmrd) and remained on study for 56 weeks. In the RBA sub-study, G3 (50 mg) produced comparable exposures to G1 (450-900 mg range) (Figure B) and was, therefore, selected as the starting dose for use in the R/R AML study. Six patients were treated with a continuous dosing of 50 mg BID G3; with plasma levels of 274 ng/mL and 195 ng/mL LUX observed by the end of C1D15 and C1D22 respectively. No drug related Grade ≥3 TEAEs or DLTs were observed in 50 mg BID G3 LUX treated patients; with no new safety signals observed for the G3 formulation. Based on these findings and expected exposures for higher dose levels, the cohort safety review committee has approved escalation of G3 dosing to 200 mg BID at which dosing is ongoing. CONCLUSIONS: LUX has a favorable safety profile in patients at all tested dose levels, for multiple cycles, for both studies. Antitumor activity was observed in a heavily pretreated relapsed AML patient and in multiple B-NHL subtypes and CLL/SLL patients including several with prior ibrutinib exposure. Continuous dosing of patients with R/R AML and Higher-Risk MDS with the G3 formulation is ongoing; with updated clinical data (200 mg dose level) to be presented at the meeting
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial
No full textBACKGROUND: Pomalidomide and dexamethasone is a standard of care for patients with multiple myeloma in whom bortezomib and lenalidomide treatment has failed. KEYNOTE-183 assessed efficacy and safety of pomalidomide and dexamethasone with or without pembrolizumab in patients with relapsed or refractory multiple myeloma. Here, we present the findings of an unplanned, ad-hoc interim analysis at the request of the US Food and Drug Administration (FDA). METHODS: KEYNOTE-183 was a randomised, open-label, phase 3 trial done at 97 medical centres across 11 countries (Australia, Canada, France, Germany, Israel, Italy, Japan, New Zealand, Norway, Spain, and USA). Patients aged at least 18 years with multiple myeloma, an Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1, previously treated with at least two lines of therapy (excluding pomalidomide) and refractory to the last line were randomly assigned 1:1 to the pembrolizumab plus pomalidomide and dexamethasone group or the pomalidomide and dexamethasone group via an interactive voice response or integrated web response system. Patients received oral pomalidomide 4 mg daily on days 1-21 and oral low-dose dexamethasone 40 mg on days 1, 8, 15, and 22 in 28-day cycles, with or without intravenous pembrolizumab 200 mg every 3 weeks. The dual primary endpoints were progression-free survival and overall survival. Efficacy was assessed in all randomly assigned patients and safety was assessed in patients who received at least one dose of study treatment. The trial is registered at ClinicalTrials.gov, number NCT02576977, and it is closed for accrual. FINDINGS: Between Jan 18, 2016, and June 7, 2017, 249 patients were randomly assigned to either the pembrolizumab plus pomalidomide and dexamethasone group (n=125) or the pomalidomide and dexamethasone group (n=124). On July 3, 2017, the FDA established that risks associated with the triple combination outweighed benefits and halted the study. Median follow-up was 8·1 months (IQR 4·5-10·9). Median progression-free survival was 5·6 months (95% CI 3·7-7·5) in the pembrolizumab plus pomalidomide and dexamethasone group versus 8·4 months (5·9-not reached) in the pomalidomide and dexamethasone group; progression-free survival estimates at 6 months were 48% (95% CI 37-58) versus 60% (49-69) at 6 months (hazard ratio [HR] 1·53; 95% CI 1·05-2·22; p=0·98). Median overall survival was not reached (95% CI 12·9-not reached) versus 15·2 months (12·7-not reached; HR 1·61; 95% CI 0·91-2·85; p=0·95); overall survival estimates at 6 months were 82% (95% CI 74-88) versus 90% (82-95). Serious adverse events occurred in 75 (63%) of 120 patients in the pembrolizumab plus pomalidomide and dexamethasone group versus 56 (46%) of 121 patients in the pomalidomide and dexamethasone group. Four (3%) treatment-related deaths occurred in the pembrolizumab plus pomalidomide and dexamethasone group (one each of unknown cause, neutropenic sepsis, myocarditis, and Stevens-Johnson syndrome); myocarditis and Stevens-Johnson syndrome were considered related to pembrolizumab. No treatment-related deaths were reported in the pomalidomide and dexamethasone group. INTERPRETATION: The results from this unplanned, FDA-requested, interim analysis showed that the benefit-risk profile of pembrolizumab plus pomalidomide and dexamethasone is unfavourable for patients with relapsed or refractory multiple myeloma. FUNDING: Merck Sharp & Dohme, a subsidiary of Merck & Co (Kenilworth, NJ, USA)
Prospective Observational Study of Pazopanib in Patients with Advanced Renal Cell Carcinoma (PRINCIPAL Study)
No full textBackground: Real-world data are essential to accurately assessing efficacy and toxicity of approved agents in everyday practice. PRINCIPAL, a prospective, observational study, was designed to confirm the real-world safety and efficacy of pazopanib in patients with advanced renal cell carcinoma (RCC). Subjects, Materials, and Methods: Patients with clear cell advanced/metastatic RCC and a clinical decision to initiate pazopanib treatment within 30 days of enrollment were eligible. Primary objectives included progression-free survival (PFS), overall survival (OS), objective response rate (ORR), relative dose intensity (RDI) and its effect on treatment outcomes, change in health-related quality of life (HRQoL), and safety. We also compared characteristics and outcomes of clinical-trial-eligible (CTE) patients, defined using COMPARZ trial eligibility criteria, with those of non-clinical-trial-eligible (NCTE) patients. Secondary study objectives were to evaluate clinical efficacy, safety, and RDI in patient subgroups. Results: Six hundred fifty-seven patients were enrolled and received ≥1 dose of pazopanib. Median PFS and OS were 10.3 months (95% confidence interval [CI], 9.2–12.0) and 29.9 months (95% CI, 24.7 to not reached), respectively, and the ORR was 30.3%. HRQoL showed no or little deterioration over time. Treatment-related serious adverse events (AEs) and AEs of special interest occurred in 64 (9.7%), and 399 (60.7%) patients, respectively. More patients were classified NCTE than CTE (85.2% vs. 14.8%). Efficacy of pazopanib was similar between the two groups. Conclusion: PRINCIPAL confirms the efficacy and safety of pazopanib in patients with advanced/metastatic RCC in a real-world clinical setting. Implications for Practice: PRINCIPAL is the largest (n = 657) prospective, observational study of pazopanib in patients with advanced/metastatic renal cell carcinoma, to the authors’ knowledge. Consistent with clinical trial results that often contain specific patient types, the PRINCIPAL study demonstrated that the effectiveness and safety of pazopanib is similarly safe and effective in patients with advanced kidney cancer in a real-world clinical setting. The PRINCIPAL study showed that patients with advanced kidney cancer who are treated with first-line pazopanib generally do not show disease progression for approximately 10 months and generally survive for nearly 30 months
The use of fly ash to stabilise low concentrations of mercury in the environment
No full textThe work investigates if fly ash from Ekibatuz Power Plant can stabilise low concentrations of mercury in the environment and prevent it from becoming soluble in water and in preventing it transforming into the methylated form. The work demonstrates that mercury bound to fly ash from the coal fired 4,000 Mwatt Ekibatuz Power Plant in Kazakhstan is fairly stable at pH levels that are found in most natural water bodies. The adsorption behavior followed the Freundlich adsorption model. The adsorption capacity of the fly ash for Hg (II) was found to be 3.0 mg.g-1 of dry ash, the adsorption equilibrium being reached after 96 hours. The adsorption kinetic and studied at pHs between 6 and 8. The study showed that between the pH range of 6.0 and 8.0 bound mercury on wet and air dried ash was fairly resistant to leaching with the maximum leaching being 0.292 mg.l-1 and 0.14 mg.l-1 for the wet and air dried fly ash, respectively, with leachate at pH 7.0. Laboratory studies of the stability of the adsorbed mercury on fly ash when mixed with organic rich sediments in an anaerobic environment at pH 7.0 showed that despite ideal conditions for methylation to take place after 8 weeks, the concentration in solution was less than 2 ?g.l-1. The studies showed that unburnt carbon contained in raw fly ash was the key factor for adsorption reaction. The results indicated that fly ash from the 4,000 Mwatt Ekibatuz Power Plant in Kazakhstan fired with high ash medium volatile coal can be used to stabilise low concentration of mercury in the natural aquatic environmen
Instructional strategies for building African-American males' self-efficacy
No full textPlan BThe purpose of this study was to determine if The Efficacy Curriculum would increase self-efficacy in African American male high school students exposed to the curriculum in technology education classes. African American males are a group whose academic achievement has lagged behind that of other groups. The design of the study was a pre-experiment study of difference. The Student Self-Efficacy Instrument was administered to the students at the beginning of their ninth grade school year to determine their self-efficacy level. The Efficacy Curriculum was delivered as a curricular theme for the technology education content for a period of a semester and then the instrument was re-administered to determine the students' level of self-efficacy after the instruction.
The study found that the students' levels of self-efficacy did increase as a result of the use of the Efficacy Curriculum. The curriculum was also postulated to change the students' conceptualization of self-efficacy and also to increase the students' levels of another variable, academic responsibility, to an even greater extent than found with the self-efficacy variable.
The self-efficacy variable has been shown in the past to be a strong determinating factor in higher academic achievement in students whose self-efficacy was determined to be at high levels
Childhood mourning : a critical evaluation of psychoanalytic views.
No full textThere is dissention among psychoanalysts about mourning in childhood, including the criteria appropriate to define mourning, the intrapsychic processes of mourning, the ways these manifest in grief and the factors affecting the outcome of childhood bereavement. In order to place the controversies in context, research on adult mourning, both psychoanalytic and empirical, is first reviewed. Psychoanalytic contributions on childhood mourning, with particular reference to parent loss are then examined, and it is .contended that Klein's theoretical formulations have been under utilised in illuminating childhood bereavement reactions. Questions raised but unanswered by the psychoanalytic literature on childhood parent loss are considered-to be whether the loss of a primary love object has specific repercussions, either in affecting mourning or the child's ongoing development in the parent's absence; whether the therapeutic relationship has been necessary to facilitate mourning in the case-reports discussed; whether generalisations are being made from an unrepresentative sample; and what role cognitive conceptions of death have in affecting bereavement reactions
